Skip to Content

Monovisc Approval History

FDA Approved: Yes (First approved February 24, 2014)
Brand name: Monovisc
Generic name: sodium hyaluronate
Dosage form: Injection
Company: Anika Therapeutics, Inc.
Treatment for: Osteoarthritis

Monovisc (sodium hyaluronate) is a viscoelastic supplement indicated for the treatment of pain associated with osteoarthritis of the knee.

Development History and FDA Approval Process for Monovisc

DateArticle
Feb 27, 2014Approval FDA Approves Monovisc, a New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide